Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy - Wikidata - awgldk - TriplyDB

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

http://www.wikidata.org/entity/Q36689936

about

Preadministration of High-Dose Salicylates, Suppressors of NF- B Activation, May Increase the Chemosensitivity of Many Cancers: An Example of Proapoptotic Signal Modulation Therapy Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxane The first draft of the endostatin interaction network Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?Metronomic Chemotherapy--A New Path to Treat Advanced Non-small Cell Lung Cancer CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1 A novel cancer therapeutic using thrombospondin 1 in dendritic cells Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.Normalization of the vasculature for treatment of cancer and other diseases.Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer.Capecitabine "metronomic" chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy.Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatment.Antivascular therapy for epithelial ovarian cancer.Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors.Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer.Antiangiogenic activity of 2-deoxy-D-glucose.A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma Contribution of host-derived tissue factor to tumor neovascularization VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment.Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care Increased tumor oxygenation and drug uptake during anti-angiogenic weekly low dose cyclophosphamide enhances the anti-tumor effect of weekly tirapazamine.The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy.Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma.Continuous low-dose (metronomic) chemotherapy on rat prostate tumors evaluated using MRI in vivo and comparison with histology A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.sFRP-1 binds via its netrin-related motif to the N-module of thrombospondin-1 and blocks thrombospondin-1 stimulation of MDA-MB-231 breast carcinoma cell adhesion and migration.Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer.Angiogenesis: a curse or cure?The anti-angiogenic basis of metronomic chemotherapy.Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model Mechanistic Effects of Calcitriol in Cancer Biology DNA vaccines suppress tumor growth and metastases by the induction of anti-angiogenesis.Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.

P2860

Q22299231-850E0940-12C0-4E70-A202-E0032468C8EA Q24314623-A34793EA-4A4E-4AFD-98FE-469C4589ADC9 Q24338820-95F9D53E-360A-4035-B5A3-05CF80F2A50F Q24794969-77E82CCA-9184-4D95-8D1A-9AE4079CAF62 Q27015786-63C520F3-1E2B-4A7A-A0E9-28C9A0562E13 Q28251463-70990A9B-EF7A-46D9-BDA1-E87F608BE7DC Q28395685-7A9AEB87-E53B-43C7-AF10-05A3C472A030 Q30439565-9DDB6313-158C-4CF3-A1CE-D56C76295EB9 Q30441458-71C3E9A8-8774-4385-BC16-5539A5D1E706 Q30469815-5A7C0801-966A-4A31-8C16-C6C977BD4F98 Q30471456-6F2A9C82-2940-4428-A461-55EFD78C1490 Q33282055-6EC7FFBA-6D7C-4B9B-933A-4CF4B9F35798 Q33393811-66BE9940-DEAD-4364-AB7F-91FBE9133E82 Q33395123-2DD196FC-CED9-418A-9E1D-CEA41676736A Q33583598-47CFC29C-F2FE-4B90-A310-E9307E85BDAC Q33618884-94A79821-9C0B-49CE-B0A7-AA05CE01C6B4 Q33720164-DCF27229-6077-486C-9A84-CC15702F794E Q33727047-DA52C322-BB93-40E6-AAC0-BEDAC480ED3D Q33742196-81641A62-68BB-4858-97E3-C6ABF058B513 Q33759537-23D4150A-AE93-44E0-81F2-832A38F7EB9B Q33765271-BB555F05-E6B5-4157-A184-976806731A6F Q33772197-45CD3EA1-6C12-4887-9ED2-3B1416096BBF Q33780751-7FEA8768-6C8E-4106-9559-EF41863E45C8 Q33794896-9433142B-8996-4E43-BA7E-BCEE4FE9BF1C Q34028780-05AA45D8-29C6-4DC1-8256-460082FAE6F0 Q34052424-B2734B86-DEBA-4A36-A18D-6A4C46778F7C Q34346752-13D50668-1F84-4C78-A98C-6DF9C5A6B46E Q34633657-34D1FFBB-410D-4EC7-BE63-E979C3A930E3 Q34768926-47955669-BBBE-4A4F-A914-A1FE8A467E55 Q34851156-DFF785A6-355B-415B-9603-229978BF6DCF Q34904445-2FCA677D-F2FE-4B16-B4FC-72E0330F3222 Q35027024-E5729FAF-60B3-4F39-8CDE-1793B89938F5 Q35034703-8EB9AB3A-7EF7-4366-A097-D8B515936AE5 Q35247727-7B4EF7A3-DB61-4926-8357-A947CBAC8097 Q35521647-4BEBFC25-FD8F-480C-A430-CDE05FC756F6 Q35788112-C890F20D-B960-4699-8D41-50BC96DCE30F Q35800657-F19C2AEE-A148-4365-BB22-67B621BB37D2 Q35809076-7ED2BDAF-5C11-48F6-9E17-C7F48AA1114B Q35826396-337D3E82-65FE-46F1-BA56-005EA8E7CBE9 Q35834220-B5FD1427-DED4-47BD-9125-E70B90FC3CAD

P2860

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

http://www.wikidata.org/entity/Q36689936

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Thrombospondin 1, a mediator o ...... w-dose metronomic chemotherapy

@ast

Thrombospondin 1, a mediator o ...... w-dose metronomic chemotherapy

@en

type

label

Thrombospondin 1, a mediator o ...... w-dose metronomic chemotherapy

@ast

Thrombospondin 1, a mediator o ...... w-dose metronomic chemotherapy

@en

prefLabel

Thrombospondin 1, a mediator o ...... w-dose metronomic chemotherapy

@ast

Thrombospondin 1, a mediator o ...... w-dose metronomic chemotherapy

@en

P1433

Q36689936-2F47A02C-593D-446A-BB63-0BD4114FA02B

P1476

Q36689936-A261B975-7FDE-4057-85F2-711E7B7AFC51

P2093

Q36689936-9D9D0A79-CEC5-4FC7-A287-7682C300F268

Q36689936-D7B4F7C0-06F4-4A80-80CC-B9D65924799E

Q36689936-E3DF7823-260A-4EF8-85C9-9B3915735FF3

Q36689936-F3C39D99-70EF-4228-90C3-C4481BCA9879

Q36689936-FE853B9D-32EC-49DE-9396-B9942ABF20BA

P2860

Q36689936-0662628E-567C-4826-99CD-294D4E710B37

Q36689936-12429E62-57E1-4333-B76C-23817ED59FEF

Q36689936-1FF059FB-686B-4DF7-9ECF-880E4AE19E00

Q36689936-231B9E5C-3E85-4663-884E-E48F0EF05D96

Q36689936-2AB3380B-6D66-4731-B05B-F29720E0F04D

Q36689936-38BF2D3F-40E9-4062-92B7-65DCE1626E4C

Q36689936-4607E1D4-296D-4C6A-82C6-DE9F31F48109

Q36689936-47B95C42-0E5B-4455-93D5-A7DF97981274

Q36689936-4DB8F5C0-4740-49E2-B54B-98D0C8F59643

Q36689936-6144D216-0515-4390-9F1F-052E86298FAC

P304

Q36689936-D38BAEB8-9B53-4FDE-8AFE-99CB805FC938

P31

Q36689936-682E5E7D-9C4D-4F25-B44B-2E7CC53A6A99

P356

Q36689936-B491383E-3563-41C9-A9BD-8E2DA46629BB

P407

Q36689936-A6DBB372-89F4-4C85-AEC4-5B2DBDCAC209

P433

Q36689936-DFB63816-4EA4-4AA2-89B2-6CE397AA46A9

P478

Q36689936-EABCA923-0420-42FE-89F3-7BC5F71EAD69

P577

Q36689936-0F2669B9-D9C7-4615-BA42-29943261C342

P5875

Q36689936-530FDD31-E934-4138-B485-14725CAB9214

P698

Q36689936-13BAAF3E-4B3B-4428-BB2C-440A4B1D9E88

P921

Q36689936-7DB8A991-EB38-404D-8844-EF9A352A0740

P932

Q36689936-3DC5B1CD-2B1F-4B31-9667-3BA20554EB3C

P356

PNAS.2135406100

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Thrombospondin 1, a mediator o ...... w-dose metronomic chemotherapy

@en

P2093

Giulio Francia

http://www.w3.org/2001/XMLSchema#string

Guido Bocci

http://www.w3.org/2001/XMLSchema#string

Jack Lawler

http://www.w3.org/2001/XMLSchema#string

Robert S Kerbel

http://www.w3.org/2001/XMLSchema#string

Shan Man

http://www.w3.org/2001/XMLSchema#string

P2860

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

Interferon alfa-2a therapy for life-threatening hemangiomas of infancy.

The cell biology of thrombospondin-1.

Redefining the target: chemotherapeutics as antiangiogenics.

Thrombospondins and tumor angiogenesis.

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents.

P304

12917-12922

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.2135406100

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P577

2003-10-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

9048418

http://www.w3.org/2001/XMLSchema#string

P698

14561896

http://www.w3.org/2001/XMLSchema#string

P921

P932

240719

http://www.w3.org/2001/XMLSchema#string